View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 7, 2015

Roche’s Avastin plus chemotherapy receives European approval for cervical cancer

Switzerland-based Roche has received approval from the European Commission for its Avastin (bevacizumab) in combination with standard chemotherapy to treat adult patients with persistent, recurrent or metastatic carcinoma of the cervix.

Cervix

Switzerland-based Roche has received approval from the European Commission for its Avastin (bevacizumab) in combination with standard chemotherapy to treat adult patients with persistent, recurrent or metastatic carcinoma of the cervix.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

Approval has been granted in combination with standard chemotherapy, including paclitaxel and cisplatin or alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy to treat an advanced cervical cancer.

Roche global product development head and chief medical officer Dr Sandra Horning said: "We are pleased that women in Europe now have a much needed new treatment option that is proven to help them live longer lives compared to chemotherapy alone.

"Currently, fewer than one in six women with this disease are alive five years after diagnosis. Avastin’s approval is a welcome advance for women with persistent, recurrent or metastatic carcinoma of the cervix."

Approval was based on results of the pivotal GOG-0240 study, which demonstrated that women who received Avastin plus chemotherapy had a statistically significant 26% reduction in the risk of death compared against women who received chemotherapy alone.

"Avastin’s approval is a welcome advance for women with persistent, recurrent or metastatic carcinoma of the cervix."

GOG-0240 is an independent and National Cancer Institute (NCI)-sponsored study of the Gynecological Oncology Group (GOG) that evaluated the efficacy and safety profile of Avastin plus chemotherapy in women with persistent, recurrent or metastatic carcinoma of the cervix.

In August 2014, Avastin in combination with paclitaxel and cisplatin or paclitaxel and topotecan chemotherapy received approval in the US, based on the same GOG-0240 data.

The same combination also received approval in Switzerland in December 2014 and in six other countries to treat women with persistent, recurrent or metastatic carcinoma of the cervix.

Avastin initially received approval in the US in 2004 to treat colorectal cancer and is also approved in Europe to treat advanced stages of breast cancer, colorectal cancer, non-small cell lung cancer, kidney cancer and ovarian cancer.


Image: Cervical cancer seen on a T2 weighted saggital MR image of the pelvis. Photo: courtesy of Rádiológ.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology